Clinical Trials Directory

Trials / Conditions / Adenocarcinoma of the Stomach

Adenocarcinoma of the Stomach

27 registered clinical trials studyying Adenocarcinoma of the Stomach — 7 currently recruiting.

StatusTrialSponsorPhase
WithdrawnMolecular Analysis of Gastric and OEsophageal Cancers STudy
NCT06702384
Royal Marsden NHS Foundation Trust—
Not Yet RecruitingTherapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
NCT07014254
Xijing HospitalN/A
Not Yet RecruitingPhase IIT Trial of SNA014
NCT06646783
SmartNuclide BiopharmaEARLY_Phase 1
TerminatedNM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT06299163
Numab Therapeutics AGPhase 1
RecruitingPerioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcino
NCT05872685
Yu jirenPhase 2
Not Yet RecruitingPerioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esop
NCT05970627
Yu jirenPhase 2
RecruitingPerioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Aden
NCT05729646
Yu jirenPhase 2
RecruitingPerioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esop
NCT05715931
Yu jirenPhase 2
RecruitingRadiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cance
NCT06121700
Fudan UniversityPhase 2
UnknownA Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
NCT05315830
The First Affiliated Hospital of Bengbu Medical UniversityPhase 1
Active Not RecruitingRadiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
NCT04878783
University of Roma La Sapienza—
UnknownEGFR-targeted Therapy for Gastric Cancer
NCT04077255
National Cancer Center, KoreaPhase 2
UnknownAvelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
NCT03966118
P. C. Thuss-PatiencePhase 2
TerminatedRegorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcin
NCT03722108
UNICANCERPhase 1 / Phase 2
CompletedModified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untrea
NCT03647969
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestPhase 2
Active Not RecruitingPlanning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
NCT02678182
Royal Marsden NHS Foundation TrustPhase 2
TerminatedA Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
NCT02202759
Millennium Pharmaceuticals, Inc.Phase 2
UnknownEarly Oral Feeding After Total Gastrectomy for Cancer
NCT01962519
Jagiellonian UniversityN/A
CompletedExplorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal
NCT01472029
AIO-Studien-gGmbHPhase 2
TerminatedVeliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
NCT01233505
National Cancer Institute (NCI)Phase 1
UnknownTesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
NCT01095120
Genta IncorporatedPhase 2
TerminatedPharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma
NCT00871273
Cambridge University Hospitals NHS Foundation TrustPhase 4
CompletedCombination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastr
NCT00982592
National Cancer Institute (NCI)Phase 2
CompletedSaracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Canc
NCT00607594
National Cancer Institute (NCI)Phase 2
CompletedOxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydroch
NCT01561014
Wake Forest University Health SciencesPhase 1
CompletedIntergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach
NCT01640782
Mario Negri Institute for Pharmacological ResearchPhase 3
TerminatedFR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
NCT00098527
National Cancer Institute (NCI)Phase 2